A year ago, Boston Scientific Corp. president and CEO Jim Tobin was outlining his steps to fix its newly acquired prize, Guidant, which he said had been languishing with operational and quality control problems, particularly in its much-prized ICD business. [See Deal] (See "How to Fix a Guidant: Boston Scientific's Tobin Opens Playbook," IN VIVO, December 2006 Also see "How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook" - In Vivo, 1 December, 2006.)
While those clean-up activities are still underway, Boston Scientific management has spent the last few months looking within to find...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?